Trading update19 Sep 2020 07:01
Having another reread over morning tea
The Company's market leading position in COVID-19 PCR testing has resulted in an increased customer base and a reputation for innovation and high performance of our products, enabling us to forge a number of strategic partnerships.
A number of strategic partnerships very nice.
Novacyt's near-term focus is to deliver strong organic revenue growth in the core business, where the Directors believe demand for its products will continue to grow into at least H1 2021 as COVID-19 testing continues. In the medium-term, Novacyt expects to leverage its reputation, market intelligence and relationships developed during the COVID-19 response to commercialise new products, as well as expand its presence in respiratory and transplant clinical diagnostics, to meet significant unmet market needs.
UNMET MARKET NEEDS (emphasis)
revenue for the second half of the year is expected to be greater than the first half of the year and margins to be at least at a similar level.
Bearing in mind all the new staff the above re margins is incredible.
From the CEO's comment
The Company has significantly increased its customer base, has built a recognised reputation for the performance of its products, formed multiple new and significant strategic partnerships and established an influential position in UK diagnostic testing.
There it is again but this time MULTIPLE new and significant partnerships.
Then this super important sentence
In the UK, the government has a goal of supporting and creating a national diagnostics industry that can compete on the global stage.
More tea I think.